Deutsche Bank AG Sells 514,044 Shares of Repligen Co. (RGEN)

Deutsche Bank AG lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 72.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 196,880 shares of the biotechnology company’s stock after selling 514,044 shares during the quarter. Deutsche Bank AG’s holdings in Repligen were worth $10,382,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RGEN. First Hawaiian Bank bought a new position in shares of Repligen during the fourth quarter worth approximately $28,000. Enlightenment Research LLC bought a new position in shares of Repligen during the fourth quarter worth approximately $42,000. Parallel Advisors LLC increased its stake in shares of Repligen by 485.1% during the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 1,043 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in shares of Repligen by 16.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 214 shares during the period. Finally, Advisory Services Network LLC increased its stake in shares of Repligen by 10.7% during the fourth quarter. Advisory Services Network LLC now owns 1,771 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 171 shares during the period. Institutional investors own 91.18% of the company’s stock.

RGEN has been the topic of a number of recent research reports. ValuEngine lowered Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research note on Wednesday, December 19th. Finally, BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $59.20.

In other Repligen news, VP Ralf Kuriyel sold 2,240 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $58.53, for a total transaction of $131,107.20. Following the transaction, the vice president now owns 21,043 shares in the company, valued at approximately $1,231,646.79. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Anthony Hunt sold 14,550 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $59.63, for a total value of $867,616.50. Following the transaction, the chief executive officer now owns 219,616 shares in the company, valued at approximately $13,095,702.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,437 shares of company stock worth $2,855,032. Corporate insiders own 1.40% of the company’s stock.

Repligen stock opened at $54.20 on Thursday. Repligen Co. has a one year low of $36.41 and a one year high of $70.50. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 74.25, a P/E/G ratio of 3.83 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 21st. The biotechnology company reported $0.21 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.21. Repligen had a return on equity of 5.51% and a net margin of 8.56%. The firm had revenue of $51.90 million for the quarter, compared to analyst estimates of $50.27 million. During the same quarter last year, the company earned $0.20 EPS. The company’s revenue was up 24.8% on a year-over-year basis. On average, equities analysts forecast that Repligen Co. will post 0.83 earnings per share for the current year.

WARNING: “Deutsche Bank AG Sells 514,044 Shares of Repligen Co. (RGEN)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2019/04/18/deutsche-bank-ag-sells-514044-shares-of-repligen-co-rgen.html.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Story: Penny Stocks, Risk and Reward Factors

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit